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Antigens on human platelets are categorized
according to their biochemical nature into carbohy-
drate antigens on glycolipids and glycoproteins (GPs)
(A, B, O, P, Le antigens), protein antigens (human
leukocyte antigens [HLA] Class-I A, B, and C,GPIIb/IIIa,
GPIb/IX/V), and haptens (quinine, quinidine, heparin,
and some antibiotics, e.g., penicillins and
cephalosporins).
Many platelet antigens are shared with other blood
cells,e.g.,ABO and HLA class I antigens,but some of the
glycoprotein antigens are expressed predominantly on
platelets. These antigens are commonly referred to as
platelet-specific alloantigens or human platelet
alloantigens (HPAs), although some of these are also
present to a lesser extent on other blood cells, e.g.,
HPA-5 on activated T lymphocytes.
Human Platelet Alloantigens
There are a number of well-characterized biallelic
platelet alloantigen systems, and a number of rare,
private, or low-frequency antigens have also been
described (Table 1). Most of these antigens were first
discovered during the investigation of cases of neonatal
alloimmune thrombocytopenia (NAIT).
Platelet-specific alloantigens are located on platelet
membrane GPs involved in hemostasis through
interactions with extracellular matrix proteins in the
vascular endothelium and plasma coagulation proteins.
The majority of these antigens are on the GPIIb/IIIa
complex, which plays a central role in platelet
aggregation as a receptor for fibrinogen, fibronectin,
vitronectin, and von Willebrand factor. Other
important GPs are GPIb/IX/V,the main receptor for von
Willebrand factor involved in platelet adhesion to
damaged vascular endothelium; GPIa/IIa, which is
involved in adhesion to collagen; and CD109, which
also appears to be a collagen receptor. Congenital
deficiency of these GPs results in bleeding disorders,
e.g., lack of GPIIb/IIIa causes Glanzmanns’
thrombasthenia, and absence of GPIb/IX/V results in
Bernard-Soulier syndrome. The expression of platelet
alloantigens located on these GPs may be altered in
these disorders, and HPA typing performed by
serologic assays (phenotyping) may give discrepant
results when compared with results obtained by
molecular typing (genotyping).
Inheritance and nomenclature
Most of the platelet-specific alloantigen systems
reported to date have been shown to be biallelic, with
each allele being codominant. Historically, systems
were named by the authors first reporting the system,
usually using an abbreviation of the name of the patient
in whom the antibody was detected. Some systems
were published simultaneously by different labora-
tories and with different names, e.g., Zw and PlA, or
Zav/Br/Hc, and only later were they found to be the
same polymorphism. In 1990, a working party for
platelet immunology of the ISBT agreed on a new
nomenclature for platelet polymorphisms, the Human
Platelet Antigen (HPA) nomenclature. Any new platelet
GP alloantigens are now accepted and named according
to guidelines established by the recently founded
International Platelet Nomenclature Committee.1
In the HPA nomenclature,each system is numbered
consecutively (HPA-1, -2, -3, and so on) according to its
date of discovery. The high-frequency allele in each
system is designated “a” and the low-frequency allele
“b.” Newly discovered systems are only officially
included when confirmed by a second party and
approved by the nomenclature committee. If an
antibody against only one allele has been reported, a
“w” (for workshop) is added after the antigen name,
e.g., HPA-10bw. One possible reason why antibodies
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Table 1 . Platelet-specific alloantigen systems
Platelet
Alternative Phenotype membrane Nucleotide Amino acid
System Antigen names fr equency* (%) glycoprotein change change
HPA-1 HPA-1a Zwa, PlA1 97.9 GPIIIa T196 Leucine33
HPA-1b Zwb, PlA2 28.8 C196 Proline33
HPA-2 HPA-2a Kob > 99.9 GPIbα C524 Threonine145
HPA-2b Koa, Siba 13.2 T524 Methionine145
HPA-3 HPA-3a Baka, Leka 80.95 GPIIb T2622 Isoleucine843
HPA-3b Bakb 69.8 G2622 Serine843
HPA-4 HPA-4a Yukb, Pena > 99.9 GPIIIa G526 Arginine143
HPA-4b Yuka, Penb < 0.1 A526 Glutamine143
HPA-5 HPA-5a Brb, Zavb 99.0 GPIa G1648 Glutamic acid505
HPA-5b Bra, Zava, Hca 19.7 A1648 Lysine505
HPA-6 GPIIIa A1564 Arginine489
HPA-6bw Caa,Tua 0.7 G1564 Glutamine489
HPA-7 GPIIIa C1267 Proline407
HPA-7bw Mo 0.2 G1267 Alanine407
HPA-8 GPIIIa T2004 Arginine636
HPA-8bw Sra < 0.01 C2004 Cysteine636
HPA-9 GPIIb G2603 Valine837
HPA-9bw Maxa 0.6 A2603 Methionine837
HPA-1 0 GPIIIa G281 Arginine62
HPA-10bw Laa < 1.6 A281 Glutamine62
HPA-1 1 GPIIIa G1996 Arginine633
HPA-11bw Groa < 0.25 A1996 Histidine633
HPA-1 2 GPIbβ G141 Glycine15
HPA-12bw Iya 0.4 A141 Glutamic acid15
HPA-1 3 GPIa C2531 Threonine799
HPA-13bw Sita 0.25 T2531 Methionine799
HPA-1 4 HPA-14bw Oea < 0.17 GPIIIa ∆ AAG1929–1931 ∆ Lysine611
HPA-1 5 HPA-15a Govb 74 CD109 C2108 Serine703
HPA-15b Gova 81 A2108 Tyrosine703
HPA-1 6 C517 Threonine140
HPA-16bw Duva < 1 GPIIIa T517 Isoleucine140
Vaa < 0.4 GPIIb/IIIa
PlT > 99.9 GPV
Vis GPIV
Pea GPIbα
Dya 38 kD GP
Moua 26 unknown
* Frequencies based on studies in Caucasians
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against the “a” antigen have not yet been reported for
many of the recently discovered systems is that the “b”
allele is of such low frequency that “bb” homozygous
individuals either do not exist or are extremely rare.
In Caucasian populations, the allele frequency for
the majority of HPA systems is skewed toward the “a”
allele and homozygosity for the “b” allele is below 3
percent. This places significant pressures on the blood
services in the management of alloimmunized patients,
as compatible RBCs and platelets are difficult to obtain
for patients with antibodies against the “a” alloantigen.
Allele frequencies vary between populations, e.g.,HPA-
1b is extremely rare or absent in the Far East, while
HPA-4b does not occur in Caucasians (Table 2). These
differences are important when investigating cases of
suspected platelet alloimmunity in different ethnic
groups.
Until the early 1990s, platelet typing was
performed by serologic assays. These assays required
the use of monospecific antisera,which were relatively
uncommon, as the majority of immunized individuals
produced HLA Class-I antibodies in addition to the
platelet-specific antibodies. Therefore, typing that
could be performed was limited, and many laboratories
were only able to phenotype for HPA-1a. The
publication of more advanced assays, such as
monoclonal antibody-specific immobilization of
platelet antigens (MAIPA) (Fig. 1), permitted more
extensive phenotyping, but some antisera were simply
not available.2
With the advent of techniques such as immuno-
precipitation of radioactive labeled platelet-membrane
proteins, and the PCR, the molecular basis of the
majority of clinically relevant platelet-specific allo-
antigen systems was elucidated. The molecular basis for
all of the HPA alloantigen systems has been determined,
and in all but one (Oea) the difference between the two
alleles is based on a single nucleotide difference that
results in a single amino acid substitution. Based on this
molecular knowledge, a plethora of molecular typing
techniques has been developed over the last decade,
and these have largely overcome problems in platelet
typing. One such assay is the PCR using sequence-
specific primers (PCR-SSP). This is a fast and reliable
molecular typing technique with minimal post-PCR
handling. It has become one of the cornerstone
techniques in HLA typing and is widely used for HPA
genotyping (Fig. 2).3,4 Novel, high-throughput, DNA-
based typing techniques with automated readout are
under development and will be used in platelet
immunology reference laboratories in the near future.
Knowledge of the genetic basis of platelet-specific
antigens makes it possible to carry out molecular
genotyping on whatever DNA-containing material is
available, e.g., platelet typing using fetal DNA from
amniocytes or from chorion villous biopsy samples.
However, in the setting of first trimester fetal HPA
typing, extreme caution is required to exclude possible
contamination with maternal cells and consequent
erroneous typing.
Platelet Antibodies
Platelet antigens can be targeted by different types
of antibodies: autoantibodies, alloantibodies, isoanti-
bodies, and drug-dependent antibodies.
Platelet Autoantibodies
Platelet autoantibodies cause the persistent
thrombocytopenia (peripheral platelet count < 150 ×
109/L) seen in idiopathic thrombocytopenic purpura
(ITP). Autoantibodies bind to platelet antigens and
cause the premature destruction of platelets in the
reticuloendothelial system.5 The main targets appear to
be the platelet membrane GP GPIIb/IIIa and GPIb/IX/V.
Such autoantibodies bind to the platelets of all
individuals, regardless of their HPA types.
ITP may be seen both in children and in adults,
where it can follow an acute or chronic course. In
adults, the condition typically has an insidious onset
and runs a chronic course. Symptoms and signs are
variable and include bruising, mucocutaneous
bleeding, and frank hemorrhage. In general, serious
bleeding symptoms are rare unless the ITP is severe
(platelet count < 30 × 109/L).6 Adult chronic ITP has an
Table 2. Platelet antigen frequencies in different populations
HPA-
1 a 1 b 2a 2b 3a 3b 4a 4b 5a 5b Naka
Caucasians 97.5 30.8 99.8 11.8 86.1 62.9 100 0 98.8 20.7 100
African blacks 100 16 97 33 85 60 100 0 96 38 97.6
Japanese 99.9 3.7 ? 25.4 78.9 70.7 99.9 1.7 99.8 8.7 97
Chinese 99.9 0.15 ? 9 78.5 71.9 99.9 0.17 99.9 17.7 85.7
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Fig. 1 . Monoclonal antibody-specific immobilization of platelet antigens. (1) A cocktail of target platelets;murine monoclonal antibody (MoMab) directed
against the glycoprotein being studied, e.g., GPIIb/IIIa; and human serum is prepared in (a) the test serum containing anti-HPA-1a and (b) no anti-
platelet antibodies. (2) After incubation, a trimeric (a) or dimeric (b) complex is formed. Excess serum and MoMab is removed by washing. (3)
The platelet membrane is solubilized in a non-ionic detergent,which releases the complexes into the fluid phase,and particulate matter is removed
by centrifugation. (4) The lysates containing the glycoprotein/antibody complexes are added to the wells of a microtiter plate previously coated
with goat anti-mouse antibody. (5) Unbound lysate is removed by washing and an enzyme-conjugated goat anti-human antibody added. (6) Excess
conjugate is removed by washing and a substrate solution is added. Cleavage of the substrate, i.e., a color reaction indicates binding of human
antibody to the target platelets.
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incidence of 58 to 66 new cases per million population
per year in the United States7 and affects predominantly
women of childbearing age.8 In children, the incidence
of ITP appears to be lower than in adults, with
published figures of between 4.0 and 5.3 per
100,000.9,10 The disorder also tends to run a different
clinical course, with an acute and abrupt onset, often
following a viral illness or immunization. The majority
of children with the disorder require no treatment, and
it resolves within 6 months. However, 15 percent of
affected children develop a chronic form of ITP similar
to that seen in adults.
The diagnosis of ITP usually relies on a typical
history,blood count,and blood film. Although there are
assays available for the detection of platelet auto-
antibodies, these are not robust enough to establish the
diagnosis of ITP alone. The direct platelet immuno-
fluorescence test (PIFT) detects platelet-associated
immunoglobulin (PAIg) levels, which are found to be
increased in most patients with ITP. Unfortunately, the
assay is not specific, since positive results can also be
seen in nonimmune thrombocytopenias, for example
secondary to septicemia.11 Assays for antibodies to
specific platelet membrane GPs IIb/IIIa and Ib/IX are
specific (90%) in ITP but less sensitive (50–65%), and
currently their routine use in the diagnosis of ITP is not
considered to be justified.12,13
Testing for platelet autoantibodies may be of value
when there is a combination of bone marrow failure
associated with immune-mediated thrombocytopenia,
in ITP patients refractory to first and second line
treatments, in drug-dependent immune thrombocy-
topenias, and in rare disorders such as acquired
antibody-mediated thrombasthenia.13
Secondary immune thrombocytopenias can occur in
association with underlying autoimmune disorders, e.g.,
systemic lupus erythematosus. Platelet autoimmunity is
also frequently associated with B-cell malignancies, and
autoantibody formation is not infrequent in the
posthematopoietic stem cell transplantation period,
during immune cell re-engraftment. In these situations,
the presence of autoantibodies might contribute to
refractoriness to donor platelets.
Platelet Alloantibodies
Detection of platelet alloantibodies
Tests for the detection of platelet-specific antibodies
have evolved over the last 4 decades. Currently the most
widely used assay is the indirect PIFT, but it is unable to
distinguish between platelet-specific and HLA Class I
antibodies. The MAIPA assay has become the gold
standard for the identification of platelet-specific
antibodies. This capture assay uses murine monoclonal
antibodies specific for platelet GPs and can analyze
complex mixtures of antibodies in patient sera. Third
generation antibody detection assays, using purified or
recombinant platelet GP, have also been developed;
however, the sensitivity of these assays is not satisfactory
for all alloantigen systems and some systems (e.g., HPA-
15) are not included.14
Clinical significance of HPA alloantibodies
HPA alloantibodies are responsible for the
following clinical conditions:
• Neonatal alloimmune thrombocytopenia (NAIT),
sometimes called fetomaternal alloimmune
thrombocytopenia (FMAIT)
• Posttransfusion purpura (PTP)
• Refractoriness to platelet transfusions
NAIT
Definition
NAIT is defined as thrombocytopenia in the
neonate (platelet count < 150 × 109/L) due to trans-
placental transfer of maternal platelet alloantibodies.
However, thrombocytopenia can also occur in utero,
Fig. 2. Simultaneous genotyping for HPA-1, -2, -3, -4, -5 and -15 by PCR-
SSP. The upper band present in all lanes is the 429-bp product of
human growth hormone. The lower bands are the products of
sequence-specific primers. Results are read from left to right, i.e.,
lane 1 is HPA-1a, lane 2 is HPA-1b, etc. The genotypes of the 3
donors shown are:
Donor 1:HPA-1b1b; 2a2b; 3b3b; 4a4a; 5a5a; 15a15a
Donor 2:HPA-1b1b; 2a2a; 3a3a; 4a4a; 5a5a; 15a15b
Donor 3:HPA-1b1b; 2a2a; 3a3a; 4a4a; 5a5b; 15a15a
Courtesy of Dr Paul Metcalfe.
HPA-1 HPA-2 HPA-3 HPA-4 HPA-5 HPA-15









94 I M M U N O H E M A T O L O G Y, V O L U M E 2 0 , N U M B E R 2 , 2 0 0 4
resulting in intrauterine death or intracranial
hemorrhage (ICH).
Incidence
The estimated incidence of severe thrombocyto-
penia due to maternal alloantibodies is 1 per 1200
pregnancies in a Caucasian population, of which the
majority are due to fetomaternal incompatibility for
HPA-1a.15 NAIT is probably underrecognized in clinical
practice.16
Pathophysiology
NAIT is the platelet equivalent of the anemia seen
in HDN. Maternal IgG alloantibodies against a fetal
platelet alloantigen cross the placenta and bind to fetal
platelets, resulting in their increased destruction in the
reticuloendothelial system. Unlike HDN, up to 50
percent of cases of NAIT occur in the first pregnancy.
In Caucasian women, the antibody most commonly
implicated in NAIT (78–89% of cases) is anti-HPA-1a.17
Anti-HPA-5b occurs more frequently in pregnancy, but
it tends to cause mild thrombocytopenia,18 and
clinically significant NAIT is less common (6–15% of
cases). The HPA-15 system,described a decade ago,has
recently been found to have clinical significance, with
HPA-15 alloantibodies being the third most frequently
encountered antibodies. Rarely,NAIT can occur due to
incompatibility for other HPA, HLA, or blood group
ABO antigens. In non-Caucasian populations, other
HPA alloantigens are more commonly implicated, for
example HPA-4b in Orientals.
Approximately 2.5 percent of pregnant Caucasian
women are HPA-1a negative and most of these women
will carry HPA-1a positive fetuses, but only about 12
percent of these women will become HPA-1a
alloimmunized.15 The ability to develop anti-HPA-1a is
HLA class II restricted, with a strong association seen
with HLA-DRB3*0101 positivity.19 As a negative
predictive factor, the absence of HLA-DRB3*0101 for
HPA-1a alloimmunization in HPA-1a negative women is
> 90 percent, but its positive predictive value as a
single marker is only 35 percent.15
The pathogenicity of antibodies in an unselected
population is highly variable. In a study including 26
cases of NAIT due to anti-HPA-1a,9 of the 26 (34%) had
severe thrombocytopenia; 35 percent (7 of 26 cases)
had a normal cord platelet count, with a further 38
percent (10/26) having a“safe”platelet count of > 50 ×
109/L.15
Clinical features
The typical infant with NAIT is full term and
otherwise healthy, with a normal coagulation screen
and isolated thrombocytopenia. The thrombocyto-
penia may be severe and unexpected, and it may occur
in the firstborn child. Clinically, the neonate may
present with petechiae, purpura, and/or ecchymoses.17
The most feared complication is ICH, which occurs in
14 to 26 percent of cases,17,20,21 resulting in death in 7
percent of affected cases20,21 and long-term morbidity
with neurologic sequelae in 21 percent.20 Eighty
percent of ICHs occur in utero, with 14 percent
occurring before 20 weeks’ and a further 28 percent
before 30 weeks’ gestation.21 This is consistent with
the expression of platelet antigens from 16 weeks’
gestation and placental transfer of IgG antibodies that
can occur from 14 weeks. There are also less common
presentations of NAIT, including fetal hydrocephalus,
hydrops fetalis, or recurrent miscarriages.22
The differential diagnoses of thrombocytopenia in
the newborn include infection, prematurity,
intrauterine growth retardation, maternal platelet
autoimmunity, and inadequate megakaryocytopoiesis
(such as in the thrombocytopenia absent radii [TAR]
syndrome).
Laboratory diagnosis
The diagnosis of NAIT requires the demonstration
of maternal platelet alloantibodies that react against
platelet-specific antigens present in the father and
infant but not in the mother. Detection of maternal
platelet-specific antibodies is usually carried out by
two techniques, the indirect PIFT and the MAIPA assay
using a panel of HPA-typed platelets. The serum of the
mother is also tested against paternal platelets by both
tests so that alloantibodies against low-frequency
alloantigens and private antigens are not missed. The
parents are also genotyped for the HPA-1,-2,-3, -5, and
-15 alloantigens (the frequency of other alloantigens
being comparatively low in the Caucasian population).
It should also be noted that in up to 30 percent of cases
of NAIT associated with fetomaternal incompatibility
for the HPA-1a antigen,maternal HPA-1a antibodies may
not be detectable.20 However, some authors have
shown that the choice of MoAb used to capture
GPIIb/IIIa in the MAIPA assay is critical and falsely
negative results may be obtained if the epitope
recognized by the MoAb is blocked by the human
antibody.23 Others have reported that an increased
serum:cell ratio is required to detect low levels of
A. NORTON ET AL.
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antibody. Sometimes the antibodies that were not
detectable at the time of delivery become detectable a
few weeks or months after delivery.
Postnatal management
The postnatal management of NAIT is influenced
by the degree of thrombocytopenia and clinical
symptoms present. Any neonate with suspected NAIT
who is bleeding or has a platelet count of < 30 × 109/L
should be transfused with compatible platelets to
minimize the risk of ICH, without waiting for
confirmatory laboratory tests.
Anti-HPA-1a and anti-HPA-5b are responsible for
approximately 75 percent and 20 percent of cases of
NAIT, respectively.17,24 Approximately 2 percent of
blood donors are negative for both these antigens and
can be easily identified using established platelet
typing methods.25,26 It is possible to establish in blood
centers a stock of HPA-1a-negative and 5b-negative
platelet concentrates from donors who donate
regularly, and these can be issued without delay for the
treatment of suspected cases of NAIT before laboratory
confir-mation of the diagnosis.27 An alternative for
platelets is random donor platelets, which, while more
readily available, have been shown to have poorer
responses, with one study of 36 cases of NAIT
reporting a median increase in platelet count 24 hours
posttransfusion of only 3.5 × 109/L.21 Washed maternal
platelets have been found to be successful in the
treatment of NAIT28 and may also be used. However,
maternal platelets need to be collected by apheresis
machines, washed to remove the maternal HPA
antibodies, which may prolong the thrombocytopenia,
and gamma-irradiated to prevent transfusion-associated
graft-versus-host disease; all of which is time
consuming and requires specialist equipment and
facilities.
In the stable neonate, an alternative approach is to
use IVIG at a dose of 1g/kg/day for 2 days. In a study
of 12 cases of NAIT, a 75 percent response rate was
reported. However, the increase in platelet count was
delayed by 24 to 48 hours.29 In urgent situations,
where antigen-negative platelets are not available and
the neonate is bleeding, a combination of random
platelets and IVIG should be given until compatible
donor platelets become available.
Monitoring of neonates with NAIT is important in
the postnatal period, irrespective of initial platelet level
and clinical symptoms. The platelet count may
continue to fall after birth, particularly in the first 48
hours, and thrombocytopenia may persist for up to 6
weeks postnatally (although 1–2 weeks is more usual).
All neonates with NAIT should also undergo some form
of cerebral imaging to exclude ICH.
Antenatal management
The realization that spontaneous ICH may occur in
utero has led many to a search for methods of
preventing serious antenatal bleeding. Unfortunately,
30 percent of cases of NAIT occur in the first
pregnancy, and at present there are no reliable tests
available to predict which women will become
alloimmunized and which of those will have severely
affected babies. What is well recognized is that
mothers with HPA-1a alloimmunization and previously
affected infants (particularly those with ICH) have a
high risk of recurrence and poor outcome in
subsequent pregnancies.30 These are the women
targeted for antenatal treatment.
In women with a known history of alloimmu-
nization and a previously affected pregnancy, HPA
typing of the partner is important. This allows the risk
of the fetus being HPA-1a positive to be assessed (i.e.,
all infants are affected when the father is homozygous
for the pathogenic platelet antigen as opposed to 50
percent of infants affected in heterozygous cases).
Where the father is heterozygous it may be useful to
HPA type the fetus by chorionic villous or amniotic
fluid sampling.
There is considerable experience in the antenatal
management of FMAIT where there has been a
previously affected pregnancy,but which is the optimal
management remains controversial.31 The therapeutic
options that have been explored are maternal
administration of IVIG and/or steroids and fetal platelet
transfusions. Early cesarean section alone is not
considered to be effective in preventing antenatal or
perinatal hemorrhage. For both approaches to
antenatal management, fetal blood sampling (FBS) has
been used for initial assessment of the fetal platelet
count, usually at 20 to 22 weeks’ gestation, and for the
monitoring of the effectiveness of treatment in the
early studies.
Bussel et al.30 found maternal administration of
IVIG to be successful, with no instances of ICH and
most, but not all, infants, achieving a platelet count of
greater than 30 × 109/L at the end of pregnancy. The
addition of steroids did not add to the effect of IVIG.
However, ICH has been found during maternal
treatment with IVIG,32 and a group of European centers
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treating 37 pregnancies only found success with the
use of maternal IVIG in 7 of 27 cases (26%), and
steroids in 1 of 10 cases (10%).33 It is difficult to under-
stand why there was such a difference in the success of
maternal administration of IVIG between these two
studies. Relevant factors may include the methods
used for assessing the success of treatment and the
dose, timing, and type of IVIG used. The selection of
cases may also be important.
A number of studies have shown the value of
platelet transfusions given by cordocentesis in raising
the platelet count, but the platelet count is raised for
only a few days. A single predelivery transfusion may
protect against bleeding at the time of delivery, but the
fetus remains at risk of spontaneous ICH earlier in
pregnancy. Weekly in utero platelet transfusions have
been shown to be effective in preventing ICH in severe
cases of FMAIT,34 but this approach is invasive.
In a recent study from the European Study Group
for NAIT, the outcome of 56 fetuses receiving antenatal
treatment for NAIT due to HPA-1a alloimmunization
compared favorably with the outcome in previous
pregnancies.35 Cases with a sibling history of antenatal
ICH or severe thrombocytopenia (platelet counts of
< 20 × 109/L) had significantly lower pretreatment
platelet counts than cases whose siblings had less
severe thrombocytopenia or postnatal ICH. Maternal
therapy resulted in a platelet count exceeding 50 ×
109/L in 67 percent of cases. None of the fetuses
managed by serial platelet intrauterine transfusions
(IUTs) suffered ICH after treatment started. However,
the most serious complications encountered by the
study cases were associated with fetal blood sampling
(FBS). The results of this study support the use of
maternal therapy as first line treatment for the antenatal
management of NAIT. The observations of this study
suggest that the commencement of maternal therapy
can be stratified on the basis of the sibling history of
NAIT. In two recent studies, concern regarding the
safety of FBS led to the use of a less invasive treatment
strategy involving maternal administration of IVIG
without FBS for monitoring of the fetal platelet count,
without an increased incidence of ICH.36,37
Antenatal treatment appears to have the potential
to improve the outcome of severely affected cases of
NAIT, but there is little information on the long-term
development of children who have been treated in
utero.
Routine antenatal screening
Advances in laboratory diagnosis and antenatal
management have drawn attention to the fact that the
first affected fetus/neonate in a family is only
recognized after bleeding has occurred, and this has
raised the question of whether routine screening for
NAIT would be advantageous.
An important initial question is whether to carry
out screening antenatally or postnatally. The advan-
tages of antenatal screening are that alloimmunized
women can be identified during pregnancy, allowing
time for antenatal intervention if it is agreed that this is
appropriate. Even if no antenatal intervention is under-
taken, the mode and timing of delivery can be planned
to ensure minimal trauma to the baby’s head and that
compatible platelets are available, if needed. Postnatal
screening can be achieved by simply carrying out a
platelet count on a cord blood sample, but the major
drawback of this approach is that the key objective of
screening, to prevent morbidity and mortality from
ICH, is unlikely to be achieved in the index pregnancy.
Although it is recognized that antenatal hemor-
rhage due to NAIT can produce devastating clinical
effects, significant shortcomings exist in the know-
ledge about NAIT necessary for the introduction of an
antenatal screening program. Further research is
required on a number of issues, including the range of
clinical outcomes in affected cases, the identification of
factors useful for predicting severe disease, and the
preferred option for antenatal management in women
with anti-HPA-1a but no previous history of affected
pregnancies.38
Posttransfusion Purpura
A clinical case of thrombocytopenia developing 7
days after elective surgery, then spontaneously
resolving 3 weeks later, was first described in 1959 by
van Loghem and colleagues.39 The 51-year-old woman
involved was found to have a strong platelet
alloantibody, subsequently described as the first human
platelet alloantibody, Zw. Two years later, a similar case
was described by Shulman and colleagues,who coined
the term posttransfusion purpura (PTP).40 In each case
the same human platelet alloantibody was implicated
(named Zw in the first case and anti-PlA1 in the case by
Shulman, now known as HPA-1a).
Definition
PTP describes an acute episode of severe throm-
bocytopenia occurring 5 to 12 days after a blood
A. NORTON ET AL.
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transfusion. It is usually seen in HPA-1a negative
women previously alloimmunized by pregnancy or
transfusion. The implicated transfusion is thought to
induce a secondary immune response, boosting the
production of HPA-1a antibodies and destruction of
transfused donor platelets. At the same time, the
patient’s own platelets are also destroyed.
Incidence
PTP is considered to be a rare complication of
transfusion, although the true incidence is unknown. A
UK-based voluntary and confidential scheme for
reporting serious hazards of transfusion (SHOT), set up
in 1996, reported 43 cases in the first 6 years of the
scheme, during which approximately 20 million blood
components were transfused, giving an approximate
incidence of 1 case in 465,000 transfusions. However,
since the introduction of universal leukoreduction of
blood components in 1999, there has been a reduction
in the annual number of cases reported to SHOT.41
As in NAIT, the susceptibility of HPA-1a negative
individuals to PTP appears to reflect their ability to
make HPA-1a antibodies, which is strongly associated
with HLA Class II –DRB3*0101.
Clinical features
The typical patient is a middle-aged or elderly
woman who has had a previous exposure to platelet
antigens through pregnancy, transfusion, or both. The
occurrence of PTP has also been reported in a small
number of male patients. The time interval between
the initial sensitizing event and the subsequent
transfusion stimulating PTP is variable, with previous
reports ranging from 3 to 52 years.
Clinically, the patient presents 5 to 12 days after
transfusion with an acute severe thrombocytopenia
(platelet count < 10 × 109/L) that has fallen from
normal within 12 to 24 hours. Associated hemorrhage
is very common and sometimes severe, with wide-
spread purpura,and bleeding from mucous membranes
and the gastrointestinal and urinary tracts. If untreated,
the condition usually lasts between 7 and 28 days,
although occasionally it may persist longer.
Implicated blood products include whole blood,
packed RBCs,and RBC concentrates. PTP has also been
reported following transfusion of plasma.
Laboratory investigations
A clinical diagnosis of PTP needs to be confirmed
by the finding of platelet-specific alloantibodies in
antigen-negative individuals. The majority of cases of
PTP (80 to 90%) are associated with the development
of HPA-1a antibodies, but other HPA antibodies have
also been implicated, including HPA-1b, HPA-3a, HPA-
3b, HPA-4a, HPA-5a, HPA-5b, HPA-15b, and Naka, and
occasionally multiple antibodies are present.
Platelet-specific antibodies are detected using the
MAIPA assay, which is able to resolve mixtures of
antibodies, including HLA antibodies, that are often
present in patients with PTP but do not appear to have
a pathological role.
Other causes of a rapid onset of severe thrombo-
cytopenia should also be excluded, such as dis-
seminated intravascular coagulation (the coagulation
screen is normal in uncomplicated cases of PTP),
autoimmune thrombocytopenia, and drug-induced
thrombocytopenia, e.g., heparin-induced thrombo-
cytopenia (HIT). Rarely, thrombocytopenia may occur
within 48 hours of a transfusion secondary to passively
transfused platelet-specific alloantibodies from an
immunized blood donor.
Pathophysiology
A rapid secondary antibody response (usually
against HPA-1a) is stimulated by the RBC transfusion,
with the result of acute thrombocytopenia about 1
week later. This time course of events is well
established. However, it is still unclear why the
patient’s own antigen-negative platelets are destroyed.
A number of hypotheses have been suggested:
• Transfused HPA-1a-positive platelets release HPA-
1a antigen, which is adsorbed onto the patient’s
HPA-1a-negative platelets, making them a target
for anti-HPA-1a. Support for this hypothesis
comes from observations such as the elution of
anti-HPA-1a from HPA-1a-negative platelets in
some cases of PTP and the demonstration of the
adsorption of HPA-1a antigen onto HPA-1a-
negative platelets after incubation with plasma
from HPA-1a-positive stored blood.
• The released HPA-1a antigen forms immune
complexes with anti-HPA-1a in the plasma and
the immune complexes become bound to the
patient’s platelets, causing their destruction.
• The transfusion stimulates the production of
platelet autoantibodies as well as anti-HPA-1a.
Evidence in favor of this mechanism is the
detection of positive reactions of some PTP
patients’ sera from the acute thrombocytopenic
phase with autologous platelets and the isolation
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of autoantibodies that recognize calcium-
dependent epitopes on GPIIb/IIIa during the
acute phase.42
• In the early phase of the secondary antibody
response, anti-HPA-1a may be produced, which
has the ability to crossreact with autologous as
well as allogeneic platelets.
Management
The main aim of treatment is to prevent morbidity
and mortality associated with severe thrombocyto-
penia by shortening the duration of thrombocytopenia.
A particular risk is ICH, which may cause early
fatalities. Prompt treatment is therefore essential, to
prevent this.
There have been no randomized controlled trials
of treatment for PTP, and comparison of various
therapeutic measures is complicated because of the
occurrence of spontaneous remissions. Currently the
treatment of choice is high-dose intravenous immuno-
globulin (IVIG) (2g/kg given over 2 or 5 days), with
rapid responses seen in about 85 percent of cases.43
Steroids and plasma exchange were the preferred
treatments before the availability of IVIG, and plasma
exchange, in particular, appeared to be effective in
some, but not all, cases.
Platelet transfusions are usually ineffective in raising
the platelet count, but they may be needed in large
doses to control severe bleeding in the acute phase,
particularly in patients who have recently undergone
surgery before their response to high-dose IVIG. There
is no evidence that platelet concentrates from HPA-1a-
negative platelets are more effective than those from
random donors; the dose probably is more important.
Prevention
PTP may recur, although this is unpredictable and
occurs many years later. Patients with a previous
episode should be issued a card to indicate that they
need special blood products, and ideally future blood
or platelet transfusions should be either autologous or
from HPA-compatible donors.
The reduction in cases of PTP reported to the
SHOT scheme since the introduction of universal
leukoreduction in the UK suggests that leukoreduced
blood products may be safe.
Refractor iness to Platelet Transfusions
Platelet transfusions are effective in decreasing
hemorrhagic complications of severe thrombocyto-
penia. They may be given therapeutically to patients
with active bleeding or prophylactically to patients
with thrombocytopenia secondary to bone marrow
failure. Serious spontaneous hemorrhage is unlikely to
occur at platelet counts above 10 × 109 /L,44 and this
level has been widely adopted as a threshold above
which prophylactic platelet transfusions are not
required in an otherwise stable, nonbleeding patient.45
Although prophylactic platelet transfusions are
standard practice for patients with bone marrow
failure, no recent randomized controlled trials have
compared therapeutic versus prophylactic transfusions
in terms of incidence of hemorrhage and associated
morbidity. Indeed, concerns about platelet refracto-
riness secondary to alloimmunization have led some to
suggest lowering the platelet transfusion threshold to
5 × 109 /L.45
Definition
Platelet refractoriness is defined as the repeated
failure to achieve satisfactory responses to platelet
transfusions. This can be assessed clinically in a
bleeding patient. However,where platelet transfusions
have been given prophylactically, response is assessed
by measuring the posttransfusion platelet count
increment.
Various formulae have been devised to assess the
platelet increment, including the percent platelet
recovery and CCI. In practice, a 24-hour increment of
< 5 × 109/L on two or more occasions is a good
indicator of refractoriness to random donor platelets.
Causes of platelet refractoriness
Refractoriness is due to the shortened survival of
the transfused platelets in the recipient’s circulation,
historically described in 20 to 60 percent of patients
receiving multiple transfusions.46 The causes may be
classified as immune or nonimmune, but in any
individual patient there may be a multifactorial
etiology.
Nonimmune clinical factors include disseminated
intravascular coagulation (DIC), splenomegaly, and
intravenous antibiotics (especially antifungal drugs
such as amphotericin B).47,48 Fever has also been
implicated in causing poor responses to platelet
transfusions, although whether this is a reflection of
sepsis, associated DIC, or antibiotic therapy rather than
the temperature itself is unclear.49 Another unknown
factor is whether platelet refractoriness may be due in
part to inadequate dosage of platelets. Further studies
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are required to assess the optimal dosage of platelets,
which may need to be adjusted according to a patient’s
blood volume.
The most common cause of alloimmune platelet
refractoriness is HLA alloimmunization. Other immune
causes include HPA alloimmunization, high titer ABO
antibodies in the recipient, platelet autoantibodies, and
drug-related platelet antibodies.
HLA antibodies predominantly occur in women
with a history of pregnancies and/or a history of
multiple transfusions. If they are suspected as a cause
for refractoriness, a combination of screening tests for
both cytotoxic and noncytotoxic HLA antibodies
should include the lymphocytotoxicity test (LCT) with
either the lymphocyte or PIFT, or an ELISA-based
method.
The role of platelet-specific antigens in platelet
refractoriness is unclear. HPA antibodies occur at a
frequency of 8 percent50 to 20–25 percent51 in various
studies and are usually found in combination with HLA
antibodies,52 although rarely they may occur in
isolation. Most commonly, HPA alloimmunization is
directed toward antigens with phenotypic frequencies
below 30 percent. Some studies have suggested that
there is no clear correlation between HPA antibodies
and poor responses to platelet transfusions,53,54 but
others have found that matching for platelet-specific
antigens in those refractory to HLA-matched platelets
may be beneficial.55
Management
The management of platelet refractoriness first
requires an assessment of possible nonimmune clinical
causes. These should be corrected if possible and
prophylactic platelet transfusions from random donors
continued in the usual way. If poor responses to
platelet transfusions persist, HLA antibodies should be
sought in the patient’s serum and, if they are present,
platelet transfusions matched for the HLA-A and -B
antigens of the patient should be used.
If poor responses continue, consideration should
be given to ABO and/or HPA incompatibility. Testing
for platelet-specific antibodies may identify HPA
antibodies, and future platelet transfusions lacking the
relevant antigen may be indicated. Platelet
crossmatching may be helpful in cases where the
platelet-specific antibodies have no obvious HPA
specificity and the only way of identifying compatible
donors is to find those who are crossmatch negative.45
ABO incompatibility is an unusual cause of platelet
refractoriness, seen usually when there are high-titer
ABO antibodies in the recipient. ABO-identical platelet
concentrates should be given to exclude this
possibility.
Prevention
Leukoreduction of blood components has been
shown to reduce the incidence of HLA alloimmu-
nization and platelet refractoriness.50
Drug-Dependent Antibodies
Drug-dependent antibodies are an important cause
of shortened platelet survival that can often be
overlooked, especially in hemato-oncology patients
who may have thrombocytopenia for a variety of
reasons. In some cases, drugs too small to elicit an
immune response by themselves may bind as a hapten
to platelet GPs in vivo. This haptenized platelet GP can
trigger the formation of antibodies that only bind to the
GP in the presence of the hapten. A classic example is
quinine and its optical stereo-isomer, quinidine.
Typically, quinine-dependent antibodies are against
GPIIb/IIIa, GPIb/IX/V, or a combination of both.
Vancomycin has also been shown to induce the
formation of IgG antibodies that bind specifically to GP
IIb, IIIa, or both in the presence of the antibiotic.56
Similarly, the interaction of heparin with platelet factor
4 can cause antibody formation and lead to a drug-
dependent thrombocytopenia.57,58 Evidence is also
emerging implicating teicoplanin as a cause of
immune-mediated thrombocytopenia.59
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